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ABSTRACT
OPTIMIZING ALGINATE-CHITOSAN MICROCAPSULES USING CO-AXIAL
AIR FLOW METHOD AS 3D STEM CELL MICROENVIRONMENT
by
Noel Alfonso
Microencapsulation of cells is gaining popular interest in the field of biomedical
engineering because it provides a more effective 3D scaffold that can mimic the cell
microenvironment.

The benefits of using microcapsules are biocompatibility,

biodegradability, nontoxicity, and formation under mild gelation conditions.

In this

study, the ability of the alginate microcapsules to control the proliferation and
differentiation of mouse OCT4-GFP embryonic stem cells is investigated. Microcapsules
are produced by extrusion of alginate into a calcium chloride gelation bath with the aid of
a co-axial air flow. It is shown that the size of the spheres is controlled based on needle
gauge, air flow rate, and alginate concentration.

Coating the microcapsules with a

chitosan membrane improves stability over time as their swelling behavior is examined.
The surface of the microcapsules is further characterized using Fourier transform infrared
(FTIR) spectroscopy and scanning electron microscopy (SEM). Permeability of the
microcapsules is studied through the release rate of encapsulated bovine serum albumin
(BSA) and fluorescein isothiocynate-dextran (FITC-dextran) over time. Finally, cell
viability is tested by means of live-dead cell and resazurin assays of encapsulated cells.
The proliferation and differentiation of encapsulated mouse OCT4-GFP embryonic stem
cells are analyzed by flow cytometry. It is shown that encapsulated cells are able to
remain viable and that the microcapsule microenvironment is able to control the
proliferation and differentiation of mouse OCT4-GFP embryonic stem cells.
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CHAPTER 1
INTRODUCTION

1.1 Microencapsulation Technology
Cell therapy is becoming one of the popular methods to replace, repair, or enhance the
function of damaged tissues or organs. Prior to use, cells are maintained and cultured in
vitro until it has reached its desired therapeutic state. The traditional methods of
manipulating cells in a two dimensional (2D) culture system, such as Petri dishes, Tflasks, or multi-wells surfaces, are becoming insufficient for the need of modern
medicine. These culturing conditions have limitations in not providing the necessary
surface area needed for cell growth. Consequently, the cells are unable to grow and
expand in a large scale, which is required in cell therapeutic applications. Another
method of using cells for therapy involves the injection of cells at the site of injury or
defect. In regenerative medicine, the injection of cells at a defect site may be problematic
as cells can not directly adhere to the tissue and could be washed away into the
surrounding environment.

The problems of 2D culture systems and cell lost at

implantation site are the reasons why injectable transporter materials, such as
microcapsules, are gaining interest as cell carriers for tissue engineering [1].

The

microencapsulation of cells is proven to be a valuable model in the research of gene
therapy, artificial cells and organs, large-scale cell culture, and drug screening [4]. Cell
microencapsulation involves the packaging of cells within a semi-permeable membrane.
This membrane allows for the bi-directional diffusion of nutrients, oxygen, secreted
therapeutic products, and metabolic wastes.

It also prevents the diffusion of high

molecular weight substances, such as antibodies and immunocytes, from the cells [4].
1

2
Microcapsules are also able to protect the encapsulated cells from the harsh external
environment and immune response of the host and thus maintaining its useful biological
activity.

The encapsulation of cells can also eliminate or reduce the use of

immunosuppressant drugs if an immune response is triggered.
In addition, microcapsules transition the two dimensional (2D) culture systems
into three dimensional (3D).

This 3D culture system provides a special

microenvironment that can affect the encapsulated cellular behaviors. Microcapsules are
able to provide a 3D matrix that better mimic the geometry, chemistry, and signaling
environment of the natural extra cellular matrix (ECM) of cells in vivo. Therefore, the
use of microcapsules can better control the encapsulated cell properties.

1.2 Cell Choice
The choice of cell type for encapsulation depends on the intended application of the
microcapsules. Various cell types such as primary cells, stem cells, and bioengineered
cells have been considered potentially therapeutic for the treatment of many diseases [6].
A potential problem associated with the encapsulation of nonautologous cells is the high
immunogenicity of the encapsulated cells which can trigger an unwanted immune
response in the microenvironment surrounding the microcapsule. This can lead to the
suffocation and death of the encapsulated cells. Additionally, differentiated cells are
limited in availability. One possible solution to overcome these problems is to choose a
cell type that can reduce the host immune response and that are readily available. Stem
cells are becoming a popular cell choice for microencapsulation technology.
Stem cells are a popular cell choice in regenerative medicine because they have
the capability of reconstituting damaged tissues and maintaining normal tissues. They

3
are also a good choice for tissues that do not have the ability to regenerate. Briefly, stem
cells are undifferentiated cells that have the ability to self-renew and differentiate. The
two major classes of stem cells are embryonic stem (ES) cells and adult stem cells. Adult
stem cells are known to be tissue specific. This means that the microenvironment in
which it came from determines the specific lineages the cell is able differentiate into. On
the other hand, embryonic stem cells have the potential of becoming more than one type
of cell and termed to be pluripotent. In either case, the differentiation of stem cells
depends on the microenvironment in which it resides.

1.3 Methods for Microcapsule Fabrication
Various fabrication methods exist for the production of microcapsules. Some of these
techniques include spray-drying, vibrating nozzle, air-blast or twin-fluid atomization,
emulsification or gelation, jet-cutting, extrusion under an electrostatic field, layer-bylayer self assembly, and milling and grinding [1, 5]. The details of each method will not
be discussed. Although each process has its advantages, it also has some disadvantages.
Each technique contains parameters that may be detrimental to the encapsulating
material. For example, the spray-drying technique is regarded as harsh because the
drying gas requires a high temperature at which is harmful to sensitive biological
materials. The vibrating nozzle and jet-cutting methods are only limited to small-scale
production. In air-blast or twin-fluid atomization, the process is complicated and the
extrusion solution is subjected to both tensile and shear stresses. Emulsification or
gelation requires many steps and rigid control of both the temperature and viscosity of
emulsion. In addition, the microcapsules must be washed thoroughly to remove the
residual oil or organic solvents. The application of an electrostatic field with a high
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voltage is known to be a limitation for the extrusion under an electrostatic field method.
The fabrication process for layer-by-layer self assembly is quite complicated. Milling
and grinding method requires large amounts of material, and this technique may result in
the denaturation of proteins due to the high pressure at the pushing and grinding inlets.
The mechanical stress may cause degradation of the proteins [5].

The choice of

technique depends on the desired properties and application under study. In particular, a
gentle encapsulation technique is required if the viability of encapsulated cells is aimed.
The fabrication method chosen for this study involves the extrusion of the microcapsule
solution through a syringe needle with an air flow jet applied at the needle tip. This
method is effective, very simply, and relatively cheap.

1.4 Microcapsule Critical Properties
Some of the favorable properties of microcapsules include mild gelation conditions,
biocompatibility, biodegradability, and nontoxicity [2]. Biocompatibility is defined as
the ability of a biomaterial to perform with an appropriate host response in a specific
application [6]. Furthermore, the microcapsule must not trigger an immune response if
implantation into a host is intended. For cell encapsulation, the microcapsule must have
sufficient permeability to allow the nutrients and oxygen to enter and the metabolic
cellular wastes products to leave the capsule in order to maintain cell viability and
promote cell growth [1, 4]. In addition, the pores must be small enough such that
unwanted large molecules will not enter or leave the capsule [1]. The microcapsules
must also be able to maintain long term stability and integrity. In cell encapsulation, the
membrane isolates the cells from the external microenvironment of the host. It must
provide a strong barrier to ensure that there is no direct cell-cell contact between the
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encapsulated cells and the host cells that can lead to an unwanted immune response. The
size of the microcapsules is also carefully considered as it found that it can influence the
immune response on the microcapsules as well [6]. Sakai et al. concluded that the
cellular reaction was much lower with the use of smaller microcapsules when compared
to microcapsules of larger diameters [7]. This study tries to achieve these requirements
necessary for the maintenance of cell function, growth, and viability of encapsulated
cells.

1.5 Biomaterials for Microencapsulation
Biomaterials, such as polysaccharide-based hydrogels, are becoming increasingly
important in the development of drug delivery systems and tissue engineering
approaches[6]. Natural polymers are typically chosen as the primary components for
microencapsulation due to their biocompatibility and biodegradability [8].

Most

microcapsules that have been developed are alginate-based with a liquid core in the
center.

Some of the advantages of using alginate include low toxicity and high

biocompatibility with the host and with enclosed cells [3].

Alginates are natural

polysaccharides derived from brown algae whose structure consists of two monomeric
units, α-L-guluronic (G) and β-D-mannuronic (M) acid residues, that are linked by 1-4
glycoside bonds [3, 8, 9]. These residues are arranged linearly in homopolymeric blocks
(GG and MM) and in heteropolymeric blocks (GM) [9]. Figure 1.1 shows the structure
of the two monomeric units of alginate and their arrangement. Alginates are highly
hydrophilic due to the presence of –OH and –COOH groups in its chains.
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Figure 1.1 Alginate is composed of two monomeric units, (a) β-D-mannuronic acid and
(b) α-L-guluronic acid. These two units are arranged linearly as shown in (c).
Source: Keita Kashima and Masanao Imai (2012). Advanced Membrane Material from Marine Biological
Polymer and Sensitive Molecular-Size Recognition for Promising Separation Technology, Advancing
Desalination, Prof. Robert Y. Ning (Ed.), ISBN: 978-953-51-0704-0, InTech, DOI: 10.5772/50734.
Available from: http://www.intechopen.com/books/advancing-desalination/advanced-membrane-materialfrom-marine-biological-polymer-and-sensitive-molecular-size-recognition-f

Alginates are also known to form gels under relatively mild conditions at room
temperature which allows the preservation of the biological activity of the encapsulated
material [8].

The simplest and widely used method for the production of alginate

microcapsules is based on the dropwise extrusion of alginate solution through a syringe
with a needle into a gelation bath containing divalent cations. The gelation of alginate
polymers is formed through cross-linking between the carboxylate anions of guluronic
acid and divalent cations [2, 8, 9]. This phenomenon is referred to as the egg-box model
in which a divalent cation binds to two carboxyl groups on the adjacent alginate
molecules [9]. The egg-box model is illustrated in Figure 1.2. The result is a highly
compacted gel network. The selection of the divalent cations is carefully considered. For
example, monovalent cations and magnesium ions (Mg2+) do not induce gelation with
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alginate. On the other hand, other divalent cations such as lead (Pb2+), copper (Cu2+),
cadmium (Cd2+), cobalt (Co2+), nickel (Ni2+), zinc (Zn2+), and manganese (Mn2+) is able
to induce gelation. However, they are not used because they are known to be toxic. The
commonly used divalent cation for the gelation of alginate is calcium (Ca2+) in calcium
chloride (CaCl2) due to its biocompatibility and nontoxicity.

Figure 1.2 The gelation of the alginate polymer is formed when a divalent cation binds
to the alginate.
Source: Keita Kashima and Masanao Imai (2012). Advanced Membrane Material from Marine Biological
Polymer and Sensitive Molecular-Size Recognition for Promising Separation Technology, Advancing
Desalination, Prof. Robert Y. Ning (Ed.), ISBN: 978-953-51-0704-0, InTech, DOI: 10.5772/50734.
Available from: http://www.intechopen.com/books/advancing-desalination/advanced-membrane-materialfrom-marine-biological-polymer-and-sensitive-molecular-size-recognition-f

The long term structural integrity of the alginate gel network is questioned given
the soft gelatinous nature of the material [10]. Since the gelation of alginate involves the
ionic interaction between negatively charged alginate molecules and positively charged
divalent cations, it may be possible for the divalent cations to diffuse out of the alginate
matrix over a prolonged period. This would cause the bond between alginate and the
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divalent cation to weaken resulting in a weaker gel that may dissolve or break [10].
Coating of the microcapsules with a polycation, such as poly-L-lysine (PLL) or chitosan,
can help stabilize the ionic gel network and reduce alginate permeability through
electrostatic interactions with the negatively charged alginate acid groups [2, 8].
Chitosan is gaining interest in replacing PLL in coating alginate microcapsules [11]. PLL
is reported to induce foreign body reactions by activating macrophages and fibroblasts
[11]. Chitosan is a naturally occurring polycationic polymer derived from the natural
polymer chitin, which is found in the exoskeleton of crustaceans and insects [2].
Chitosan is also a polysaccharide with structural characteristics

similar to

glycosaminoglycans [11]. The structure of chitosan is given in Figure 1.3.

Figure 1.3 The structure of chitosan is comprised of D-glucosamine and N-acetylglucosamine with unique polycation characteristics.
Source: Thayza Christina Montenegro Stamford, Thatiana Montenegro Stamford-Arnaud, Horacinna Maria
de Medeiros Cavalcante, Rui Oliveira Macedo and Galba Maria de Campos-Takaki (2013).
Microbiological Chitosan: Potential Application as Anticariogenic Agent, Practical Applications in
Biomedical Engineering, Dr. Adriano Andrade (Ed.), ISBN: 978-953-51-0924-2, InTech, DOI:
10.5772/54453. Available from: http://www.intechopen.com/books/practical-applications-in-biomedicalengineering/microbiological-chitosan-potential-application-as-anticariogenic-agent

Chitosan is freely available and relatively cheap compared to PLL. Furthermore,
it is known to be nontoxic and bioabsorbable. It has been investigated as a suitable
polymer coating for oral delivery of proteins as well as the immobilization or delivery of
living cells. Chitosan is soluble in acid solutions when the pH is less than 6.0. Thus,
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acetic acid is often commonly used for preparing chitosan solutions for encapsulation
processes.

Due to their excellent compatibility and nontoxicity, this study utilizes

alginate as the microcapsule material and chitosan as the coating material.

1.6 Objective
The goal of this study is to optimize alginate-based microcapsules using a co-axial air
flow method and apply these microcapsules as a 3D stem cell microenvironment.
Specifically, the aims are (1) to fabricate and characterize alginate and alginate-chitosan
microcapsules using a co-axial air flow method and (2) to evaluate cell encapsulation on
cytocompatibility and stem cell proliferation and differentiation. In this project, it is
hypothesized that the alginate-based 3D microenvironment is able to control the
proliferation and differentiation of embryonic stem cells.

CHAPTER 2
MATERIALS AND METHODS

2.1 Materials
Alginic acid sodium salt from brown algae (250 cps at 25°C, 2% solution), low molecular
weight chitosan (20 cps), coomassie brilliant blue R-250, and fluorescein isothiocynatedextran (FITC-dextran, molecular weight of 70kDa) are purchased from Sigma-Aldrich,
USA.

Anhydrous calcium chloride, sodium chloride, sodium citrate, bovine serum

albumin (BSA, bp 600-100), ethanol (95% denatured with MIKB), sodium cacodylate
(Na-cacodylate) buffer, and glutaraldehyde (25% solution) are obtained from Fisher
Scientific, USA. Glacial acetic acid is provided by Ricca Chemical Company, USA.
Fibroblast cells are cultured and maintained in fibroblast cell medium consisting
of 1% penicillin-streptomycin, 10% horse serum, and 89% Dulbecco’s Modified Eagle
Medium (DMEM) high glucose. The fibroblast cells are passaged every one to two
weeks. The medium in the tissue culture dish is replaced every three days until time of
passage. Fibroblast cells are incubated at culture conditions of 37°C and 10% CO2.
Mouse OCT4-GFP embryonic stem cells are cultured and maintained in
undifferentiation medium consisting of ESGRO Murine Leukemic Inhibitory Factor (106
units)(Millipore), 0.1mM 2-mercaptoethanol, 1.5M sodium bicarbonate, nonessential
amino acids, 4mM L-glutamine, penicillin-streptomycin, knockout serum replacement,
and knockout DMEM. The mouse OCT4-GFP embryonic stem cells are passaged every
two to three days with medium change occurring every day.

Mouse OCT4-GFP

embryonic stem cells are incubated at culture conditions of 37°C and 10% CO2.
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2.2 Preparation of Encapsulation Solutions
Sodium alginate powder and calcium chloride pellets are weighed and dissolved in
deionized water (dH2O) separately. Low molecular weight chitosan powder is weighed
and added to 0.15M CaCl2 solution making a chitosan solution of concentration 0.4%.
Next, 0.5% glacial acetic acid is added. This solution is placed on a stirring plate and
mixed overnight at room temperature to ensure dissolving. The solution is then filtered
using a cell strainer to remove any debris and impurities from the solution. The solution
is kept at 4°C until it is time to be used.

2.3 Preparation of Alginate Microcapsules
Sodium alginate is dissolved in deionized water (dH2O). The alginate microcapsules are
generally formed by extruding 1mL of alginate solution through a syringe with a needle
gauge into a gelling bath containing 20mL of 0.15M calcium chloride (CaCl2) dissolved
in dH2O. The distance from the tip of the syringe needle and the CaCl2 gelation bath is
about 5cm. An air flow by means of an air flowmeter is applied to the bottom end of the
syringe as the alginate solution is extruded. After extrusion, the alginate microcapsules
are incubated in the 0.15M CaCl2 solution for 5-10 minutes at a stirring rate of about 60
revolutions per minute (rpm). This fabrication method is illustrated in Figure 2.1.
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Syringe

Alginate Solution

Co-axial Air

Needle Gauge

Calcium
Chloride
Solution

Stirring
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Air Flowmeter

Alginate Microcapsules

Magnetic Stir Bar

Figure 2.1 The fabrication process of alginate microcapsules involves extruding the
alginate solution into a calcium chloride gelation bath under gentle stirring. An air flow
is applied at the end of the syringe needle to aid in the microsphere formation.

2.4 Optimization of Alginate Microcapsule Size
The size of alginate microcapsules can be controlled based on adjusting certain variables.
Initially in this study, the effect of needle gauge size and air flow rate are investigated.
An alginate concentration of 1.5% is used and the method of fabrication is described in
Section 2.3. Alginate microcapsules are prepared using both 22 and 30 gauge needles.
For each needle gauge, an air flow rate is applied at the needle as the alginate solution is
extruded into the CaCl2 solution under gentle stirring. Air flow rates of 0 SCFH, 7.5
SCFH, 10 SCFH, 15 SCFH, and 20 SCFH are tested. After extrusion and incubation in
0.15M CaCl2 solution, the microcapsules are transferred into p60 non-treated tissue
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culture dishes and observed under an inverted light microscope at 2x magnification.
Images are acquired via a Nikon digital camera connected to the microscope. The
microcapsules’ area, mean diameter, and shape factor are measured using SigmaScan Pro
5 software.

2.5 Swelling and Stability Test
The effect of coating the alginate microcapsules with a chitosan membrane is studied.
The swelling and stability of chitosan-coated microcapsules over time are compared with
uncoated alginate microcapsules. Microcapsules are produced as described in Section
2.3. Briefly, an alginate concentration of 1.5% is extruded through a syringe with a 30
gauge needle into a 0.15M CaCl2 solution under gentle stirring. An air flow rate of 15
SCFH is applied at the end of the syringe. Incubating the capsules in 0.4% chitosan in
0.15M CaCl2 solution for 10 minutes following incubation in CaCl2 proceeding extrusion
completion creates chitosan-coated microcapsules. Both uncoated and chitosan-coated
alginate microcapsules are washed with dH2O and incubated in phosphate buffer saline
(PBS) at room temperature.

Microcapsules are observed under an inverted light

microscope at 2x magnification until rupture is evident. Images are taken with a Nikon
digital camera connected to the microscope. The microcapsules’ area, mean diameter,
and shape factor are measured using SigmaScan Pro 5 software.

2.6 Sphere Surface Characterization
The surface comparison of uncoated and chitosan-coated alginate microcapsules is
examined. FTIR characterization is used to detect the presence and absence of chitosan
on the coated and uncoated alginate microcapsules, respectively.

In addition,
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microcapsules are stained with 5x coomassie brilliant blue R-250 and compared to
discover success of coating with chitosan. Scanning electron microscopy evaluates the
difference in topography between the two microcapsule conditions.

2.6.1 FITR
Alginate microcapsules, both coated and chitosan-coated, are fabricated according to the
aforementioned methods in Sections 2.3 and 2.5. Following the incubation in CaCl2 for
the uncoated alginate microcapsules and the incubation in 0.4% chitosan in 0.15M CaCl2
for the chitosan-coated alginate microcapsules, the microcapsules are transferred into p35
non-treated tissue culture dishes. Excess solutions are removed and the microcapsules
are washed with dH2O. The dH2O is then aspirated and the microcapsules are placed into
a vacuum desiccator to dry for at least 24 hours. After 24 hours, the microcapsules are
analyzed using Spectrum 100 FTIR Spectrometer (Perkin Elmer).

2.6.2 Microcapsule Staining with Coomassie Protein Assay Reagent
The method of manufacturing uncoated and chitosan-coated alginate microcapsules is
similar to the technique described in Sections 2.3 and 2.5. Following fabrication, the
microcapsules are washed with dH2O and incubated in 5x coomassie brilliant blue R-250
for about 10 minutes. After 10 minutes, the coomassie brilliant blue R-250 is aspirated.
The microcapsules are washed with dH2O and incubated in dH2O. Microcapsules are
observed under an inverted light microscope at 4x magnification. Images are taken with
a Nikon digital camera connected to the microscope.
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2.6.3 Scanning Electron Microscopy
Uncoated and chitosan-coated alginate microcapsules are produced following the same
protocol performed in Sections 2.3 and 2.5.

After the incubation in CaCl2 for the

uncoated alginate microcapsules and the incubation in 0.4% chitosan in 0.15M CaCl2 for
the chitosan-coated alginate microcapsules, the microcapsules are incubated in 2.5%
glutaraldehyde in 0.1M Na-cacodylate buffer (pH = 7.4) overnight at 4°C. Next, the
solution is aspirated and the microcapsules are washed with 0.1M Na-cacodylate buffer
two times. Microcapsules are dehydrated through the incubation in a series of ethanol for
5-10 minutes each.

The series are 30%, 50%, 70%, and 95% ethanol.

After the

aspiration of 95% ethanol, the microcapsules are placed in a chemical hood to air dry.
Prior to scanning the samples, the microcapsules are mounted on metal stubs using
double-sided adhesive tape, and coated with gold under a vacuum using a sputter coater
unit. The samples are then examined by scanning electron microscopy (SEM) (LEO
1350 VP).

2.7 Membrane Permeability
The membrane permeability of both uncoated and chitosan-coated alginate microcapsules
is studied through the encapsulation of BSA and FITC-dextran. The release rate of each
is monitored over time and quantified.

2.7.1 BSA Encapsulation and Sustained Release
To prepare the BSA encapsulated microcapsule, BSA is first dissolved in dH2O resulting
in a BSA stock solution concentration of 400mg/mL. The BSA stock solution is then
mixed with 2.5% alginate solution resulting in a final BSA concentration of 20mg/mL.

16
The BSA-alginate solution is extruded dropwise into 20mL of 0.15M CaCl2 under gentle
stirring through a syringe with a 30 gauge needle. An air flow rate of 15 SCFH is applied
at the needle gauge to aid in microcapsule formation. The microcapsules are incubated in
the CaCl2 at a stirring rate of 60 rpm for about 10 minutes. The microcapsules are
transferred and evenly distributed into three 3mL test tubes. Any excess CaCl2 in the test
tubes is aspirated. The microcapsules are incubated in HEPES buffer solution and the
test tube is placed into a water bath at 37°C for incubation. At time points 10, 15, 75
minutes, and days 1, 2, 3, 4, 5, 6, 7 after extrusion completion, a 1mL sample of
incubation solution is taken. The remaining solution is aspirated and replaced with 2mL
of fresh HEPES buffer solution. The Bradford colorimetric protein assay is used to
detect the amount of protein secreted from uncoated and chitosan-coated alginate
microcapsules containing BSA. Ten BSA standards are prepared using a two-fold serial
dilution beginning with BSA stock solution concentration of 500µg/mL. The incubation
solution samples and the ten BSA standards are placed into a 96-well plate and mixed
with Coomassie brilliant blue R-250. The samples and standards are analyzed by a
spectrophotometer at a wavelength of 650nm using the software SoftMax Pro.
The effect of coating the microcapsules with chitosan on the release rate of
encapsulated BSA is also tested. To create microcapsules with a chitosan coating, the
microcapsules are transferred into 0.4% chitosan solution in 0.15M CaCl2 after 10
minutes of incubation in CaCl2 under gentle stirring. The microcapsules are incubated in
the chitosan solution for 5 minutes. After 5 minutes, the same protocol for the uncoated
microcapsules is followed starting from the transfer of the microcapsules into a 3mL test
tube.
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2.7.2 FITC-dextran Encapsulation and Fluorescence Intensity
FITC-dextran encapsulated microcapsules are prepared by mixing 50mg/mL stock
solution of FITC-dextran with 2.5% alginate solution. The resulting final concentration
of encapsulated FITC-dextran is 1mg/mL.

The FITC-dextran-alginate solution is

extruded into 20mL of 0.15 CaCl2 under gentle stirring through a syringe with a 30 gauge
needle. An air flow rate of 15 SCFH is applied at the needle gauge to aid in microcapsule
fabrication. Upon extrusion completion, the microcapsules are incubated in the CaCl2
solution at a stirring rate of 60 rpm for about 5 minutes. Next, the microcapsules are
transferred into a p60 non-treated tissue culture dish. The excess CaCl2 in the dish is
aspirated, the microcapsules are washed with HEPES buffer solution one time, and fresh
HEPES buffer is added as the incubation medium. Chitosan-coated microcapsules are
created by incubating the microcapsules in 0.4% chitosan in 0.15M CaCl2 for 5 minutes
after incubation in CaCl2 following extrusion completion.

The microcapsules are

observed under a fluorescence microscope for 2 days at 2x magnification. Images of the
microcapsules are taken with a Nikon digital camera connected to the microscope. The
microcapsules’ average fluorescence intensity is measured using SigmaScan Pro 5
software.

2.8 Cell Studies
The alginate microcapsule microenvironment is explored through the encapsulation of
cells. The viability of encapsulated fibroblast cells are examined through live-dead cell
and resazurin assays. The encapsulation of mouse OCT4-GFP embryonic stem cells is
studied to determine the effect of the microcapsule environment on stem cell proliferation
and differentiation.
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2.8.1 Fibroblast Cell Encapsulation for Live-dead Cell Assay
Encapsulated fibroblast cells in alginate microcapsules are produced by mixing about 1.5
million fibroblast cells of passage 15 with 1mL of 2.5% alginate solution. The cellalginate solution is extruded through a syringe with a 30 gauge needle into 20mL of
0.15M CaCl2 at a stirring rate of 60 rpm. An air flow rate of 15 SCFH is applied at the
needle gauge. After extrusion completion, the microcapsules are incubated in the CaCl2
under gentle stirring for 5 minutes. Cells encapsulated in chitosan-coated microcapsules
are created by incubating the microcapsules in 0.4% chitosan in 0.15M CaCl2 for an
additional 5 minutes following the incubation in 0.15M CaCl2 after extrusion completion.
The microcapsules are then transferred into four wells of a 24-well tissue culture plate.
The excess CaCl2 in the wells are aspirated and the microcapsules are washed with
HEPES buffer solution one time. The microcapsules are incubated in 400µL of staining
solution for 5 minutes. The staining solution consists of HEPES buffer solution, calceinAM, and ethidium homodimer-1. After 5 minutes, the microcapsules are observed using
a fluorescence microscope at 2x magnification for live-dead cell analysis. Images are
taken by means of a Nikon digital camera connected to the microscope.

2.8.2 Fibroblast Cell Encapsulation for Resazurin Assay
The method of encapsulation of fibroblast cells is similar to that described in Section
2.8.1. After the washing of the microcapsules with HEPES buffer solution, 450µL of
fibroblast medium and 50µL of 10x resazurin solution are added to each well containing
fibroblast encapsulated spheres. The encapsulated fibroblast cells are incubated in this
solution for at least 1 hour at 37°C and 10% CO2. After 1 hour, a 100µL of the solution
is sampled from each well and placed into a 96-well plate. The remaining solution in the
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wells is aspirated and 500µL of fresh fibroblast medium is added. The 24-well plate
containing the microcapsules is incubated at 37°C and 10% CO2. The collected samples
are analyzed using a spectrofluorometer (Gemini XPS Fluorescence Microplate Reader)
that would measure the fluorescence.

The samples are measured at an excitation

wavelength of 530nm and an emission wavelength of 590nm.

The incubation and

sampling of the resazurin solution is repeated for 5 days.

2.8.3 Mouse Embryonic Stem Cell Encapsulation
About 2 million mouse OCT4-GFP embryonic stem cells of passage 41 are encapsulated
in alginate microcapsules following the same fabrication method described in Section
2.8.1 for the encapsulation of fibroblast cells. The microcapsules are transferred into p60
treated tissue culture dishes. The excess CaCl2 in the dish is aspirated and 4mL of
differentiation medium is added. The differentiation medium consists of DMEM, 10%
fetal bovine serum (FBS), 1% penicillin-streptomycin, and 4mM L-glutamine. The cells
in the alginate microcapsules are maintained in culture in differentiation medium at
culture conditions of 37°C and 10% CO2 for 2 days with medium change occurring every
day.
After 2 days of culture, the differentiation medium is aspirated and the
microcapsules are washed with PBS. In order to release the cells, the microcapsules are
incubated in 0.2% NaCl in 100mM sodium citrate solution at 37°C for 30 minutes. The
cells in solution are collected into a 15mL conical tube and PBS is added. The tube is
then centrifuged at 800rpm for 5 minutes. Following centrifuge, the supernatant is
discarded. Next, the cells are incubated in 1mL of 1.6% paraformaldehyde (PFA) for 20
minutes at room temperature. After 20 minutes, about 9mL of PBS is added. The
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mixture is centrifuged and the cells are resuspended in PBS. As a control condition,
about 1 million undifferentiated OCT4-GFP mouse embryonic stem cells of passage 42
are fixed with 1.6% paraformaldehyde following the same procedure just described. The
cells are characterized using flow cytometry by means of fluorescence-activated cell
sorting (FACS).

CHAPTER 3
RESULTS

3.1 Effect of Needle Gauge Size and Air Flow Rate on Alginate Microcapsule Size
Alginate microcapsules are fabricated by the extrusion of an alginate solution having a
concentration of 1.5% through a syringe into a 0.15M CaCl2 coagulation bath. Needle
gauges of size 22 and 30 and the application of various air flow rates at the needle end are
used to aid in the microcapsule fabrication.

Following fabrication, the alginate

microcapsules’ area, mean diameter, and shape factor are analyzed using SigmaScan Pro
5. Shape factor measures the morphology of the microcapsules, and ranges from 0 to 1.
The microcapsule can be associated to be a sphere if their shape factor value is 1 or close
to 1; otherwise to an ellipse. The results are summarized in Figure 3.1 and Table 3.1.

Figure 3.1 Alginate microcapsules are fabricated with both 22 and 30 gauge needles.
For each needle gauge, different air flow rates are applied at the needle tip. Both needle
gauge size and air flow rate affect the size of alginate microcapsules. Comparison of
microcapsule area is shown in (A) and mean diameter in (B). Data are expressed as mean
± standard deviation.
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As shown in Figure 3.1, the size of the alginate microcapsules decreases as both
the needle gauge size and air flow rate increases. All the alginate microcapsules that are
produced by both 22 and 30 gauge needles at the various air flow rates reveal no
significant difference in morphology. Most of the alginate microcapsules produced in all
conditions have shape factor values within the 0.87-0.89 range as it is given in Table 3.1.
Since these values are relatively close to 1, this indicates a round morphology for the
microcapsules.
Table 3.1 Shape Factor Analysis of Alginate Microcapsule of Various Needle Gauges
and Air Flow Rates
Air Flow Rate (SCFH)
0
7.5
10
15
20

Needle Gauge 22
0.872 ± 0.006
0.873 ± 0.013
0.881 ± 0.007
0.885 ± 0.001
0.883 ± 0.007

Needle Gauge 30
0.891 ± 0.001
0.893 ± 0.001
0.895 ± 0.002
0.897 ± 0.002
0.892 ± 0.003

3.2 Effect of Chitosan Coating on Microcapsule Stability
Adding an additional chitosan membrane on the alginate microcapsules is studied to
observe the effect it has on microcapsule stability. After the fabrication of the alginate
microcapsules using 1.5% alginate by extrusion through a syringe with a 30 gauge needle
and an air flow rate of 15 SCFH into a CaCl2 gelling bath, the microcapsules are
incubated in 0.4% chitosan in 0.15M CaCl2 solution for 5 minutes. Microcapsules are
washed with dH2O and incubated in PBS at room temperature for a few days. The
microcapsules are observed under an inverted light microscope at 2x magnification each
day until microcapsule rupture. The swelling and stability of uncoated and chitosan-
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coated microcapsules are compared. The microcapsules’ area, mean diameter, and shape
factor are analyzed using SigmaScan Pro 5. The results are represented in Figure 3.2 and
Table 3.2.

Figure 3.2 The swelling and stability of uncoated and chitosan-coated alginate
microcapsules are investigated. Microcapsules are incubated in PBS and observed under
an inverted light microscope for two weeks. Comparison of microcapsule area is shown
in (A) and mean diameter in (B). Data are expressed as mean ± standard deviation.

Referring to Figure 3.2, both uncoated and chitosan-coated microcapsules
produced from 1.5% alginate solution extruded through a 30 gauge needle with an air
flow rate of 15 SCFH have an average mean diameter of about 0.75-0.80mm following
fabrication. After the first day, all of the microcapsules show signs of swelling due to
water absorption. Uncoated microcapsules show more signs of swelling as their average
mean diameter increased to about 0.89mm which is a 14% increase. The average mean
diameter of chitosan-coated microcapsules increased 4% from their original size to
0.78mm, which is still relatively close to the average mean diameter on the first day
following fabrication.

The microcapsules continue to swell as it is evident by the

increase of mean diameter and area each day. After day 14, the mean diameter and area
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of uncoated alginate microcapsules decrease dramatically as they indicate rupture of the
microcapsules. This means that by day 14, the uncoated alginate microcapsules have
reached their maximum size. By this time the average mean diameter of the uncoated
alginate microcapsules is about 1.78mm, which is approximately a 1mm increase. The
uncoated alginate microcapsules are swelled to more than twice their original size. On
the other hand, the chitosan-coated alginate microcapsules continue to remain stable and
swell. Comparing to the maximum size of uncoated microcapsules before rupture, the
average mean diameter of chitosan-coated microcapsules is measured to be about
0.90mm. Their time of rupture is not known for monitoring ended on day 16 when the
rupture of the uncoated alginate microcapsules was observed.

The average mean

diameter of the chitosan-coated microcapsules on day 16 is about 0.91mm. Figure 3.3
shows the images of the uncoated and chitosan-coated alginate microcapsules following
fabrication and day 16.
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DAY 16

Chitosan-coated Microcapsules

Uncoated Microcapsules

DAY 0

Figure 3.3 Microscopic images of uncoated and chitosan-coated alginate microcapsules
taken on day 0 following fabrication and day 16. Images are taken with a Nikon digital
camera connected to an inverted light microscope. For the images of uncoated
microcapsules, microcapsules are viewed at 2x magnification on day 0 and at 4x
magnification on day 16.
For the images of chitosan-coated microcapsules,
microcapsules are viewed at 2x magnification on days 0 and 16. On day 0,
microcapsules are stable and have not yet swelled. By day 16, uncoated alginate
microcapsules have ruptured while chitosan-coated microcapsules remain stable.

The results illustrated in Figure 3.2 prove that coating the alginate microcapsules
with a chitosan membrane offers a more stable sphere with a reduced swelling rate
compared to uncoated alginate microcapsules.
Despite the increase in area and mean diameter over time, both uncoated and
chitosan-coated alginate microcapsules are able to maintain their circular shape as given
by their shape factor values for the 16 days of observation. All the microcapsules of both
conditions have shape factor values of about 0.89 as it can be seen in Table 3.2.
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Table 3.2 Shape Factor of Uncoated and Chitosan-coated Alginate Microcapsules
Day
0
1
2
5
7
9
12
14
16

Uncoated
0.897 ± 0.003
0.896 ± 0.001
0.894 ± 0.007
0.898 ± 0.002
0.893 ± 0.007
0.890 ± 0.004
0.897 ± 0.002
0.892 ± 0.007
0.884 ± 0.004

Chitosan-coated
0.896 ± 0.002
0.894 ± 0.005
0.896 ± 0.003
0.901 ± 0.002
0.889 ± 0.007
0.887 ± 0.014
0.892 ± 0.006
0.893 ± 0.006
0.894 ± 0.003

3.3 Characterization of Microcapsule Surface
Uncoated and coated alginate microcapsules vary from each other based on the chemical
composition on their outer surface. The surface distinction between the microcapsules is
characterized using FTIR, coomassie brilliant blue R-250 staining, and SEM.
After the fabrication and drying of the uncoated and chitosan-coated alginate
microcapsules, FTIR is used to determine the particular functional groups present on the
surface. The microcapsule FITR spectra are compared with the FTIR readings of alginate
and chitosan compounds. All samples are read at scan number 100 and a resolution at
8cm-1. Figures 3.4 and 3.5 provide the FTIR spectra for uncoated and chitosan-coated
alginate microcapsules as well as alginate and chitosan, respectively.
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Figure 3.4 The FTIR spectra of alginate and chitosan powders are compared with the
FTIR spectra of uncoated and chitosan-coated alginate microcapsules.

Figure 3.5 The surface of both uncoated and chitosan-coated alginate microcapsules are
characterized using FTIR.
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It is important to recall the chemical structures of both alginate and chitosan
presented in Figures 1.1 and 1.3, respectively, in order to associate the peaks of the FITR
spectra with the appropriate functional group. The FTIR spectrum of chitosan powder in
Figure 3.4 shows a weak band of –OH stretching at 2876cm-1. An absorption band of the
carbonyl (C=O) stretching of the secondary amide (amide I band) is observed at 1652cm1

. The bending vibrations of the N-H (N-acetylated residues, amide II band) can be found

at wavenumber at 1591cm-1. The peaks at 1423cm-1 and 1378cm-1 correspond to the NH stretching of the amide and ether bonds and N-H stretching (amide III band),
respectively. The peaks at 1065cm-1 and 1029cm-1 are the secondary (characteristic peak
of –CH-OH in cyclic alcohols, C-O stretch) and primary (characteristic peak of –CH2-OH
in primary alcohols, C-O stretch) hydroxyl groups, respectively. The strong absorption
peaks on the FTIR spectrum of alginate appear at 1598cm-1 and 1409cm-1 for the
asymmetric and symmetric stretching vibrations of carboxyl anions. The bridge oxygen
(C-O-C, cyclic ether) stretching bands are observed at 1029cm-1 [12].
The plot in Figure 3.5 shows the ability of FTIR to detect the presence of chitosan
on the alginate microcapsules. In both FTIR spectra of uncoated and chitosan-coated
alginate microcapsules, the characteristic absorption band peaks of alginate and chitosan
at 1607cm-1, 1425cm-1, 1079cm-1, and 1038cm-1 are observed. The absorption band at
1590cm-1 of chitosan in Figure 3.4 shifts to 1605cm-1 after the reaction with alginate as
seen in Figure 3.5. Although similar peaks are relatively obvious on both curves, there
are peaks that are not so noticeable that differentiates the two curves. The important peak
that is present on the chitosan-coated alginate microcapsule curve and not present on the
uncoated alginate microcapsule curve occurs at wavenumber 1564cm-1.

This peaks
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indicates the presence of a –NH2 functional group in the bending position. The detection
of the –NH2 functional group proves that chitosan can be detected on the surface of the
coated alginate microcapsules.
Next, staining the microcapsules with 5x coomassie brilliant blue R-250
following fabrication is used to detect the presence of chitosan on the surface of the
spheres.

Microcapsules are observed under an inverted light microscope at 4x

magnification and images are taken with a Nikon digital camera connected to a
microscope. The microscopic images of the stained alginate microcapsules are illustrated
in Figure 3.6.

Figure 3.6 Uncoated (A) and chitosan-coated (B) alginate microcapsules are stained
with 5x coomassie brilliant blue R-250 and compared. Staining is successful in all the
microcapsules. However, the coomassie brilliant blue R-250 is more evident in the
chitosan-coated alginate microcapsules compared to the uncoated alginate microcapsules.

Finally, scanning electron microscopy is used to examine the difference in surface
topography between uncoated and chitosan-coated alginate microcapsules. The SEM
images in Figure 3.7 show the distinction between the two conditions.

The SEM

micrographs of dried alginate microcapsules in Figure 3.7 (A) and (C) show the surface
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to be relatively smooth with a few wrinkles. The incorporation of chitosan on the
microcapsule surface does not cause any significant change in the overall shape and size.
However, the surface of chitosan-coated alginate microcapsules doesn’t seem as smooth
as the uncoated alginate microcapsules. They tend to have more wrinkles on the surface
compared to the uncoated microcapsules.

Figure 3.7 Scanning electron microscope (SEM) images (A) and (B) show an overview
at 200x magnification for uncoated and chitosan-coated microcapsules, respectively.
Images (C) and (D) show the surface structure at 1Kx magnification of uncoated and
chitosan-coated alginate microcapsules, respectively.

3.4 Permeability of Microcapsules
The permeability of the uncoated and chitosan-coated alginate microcapsules is studied
through the encapsulation of BSA and FITC-dextran. Both BSA and FITC-dextran are
encapsulated in the microcapsules through mixing with the alginate solution prior to
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extrusion into the CaCl2 coagulation bath. The microcapsules are incubated in HEPES
buffer solution over time. The release rate of each are monitored and quantified.
The permeability of BSA is analyzed through the quantification of the amount of
BSA released each day.

The measurement of the accumulated amount of BSA is

presented in Figure 3.8. The amount of BSA released from the microcapsules during the
fabrication and washing steps is shown in Figure 3.8 (A). From Figure 3.8 (A), a
significant amount of BSA is released during the initial time period, particularly during
the washing steps. An estimated amount of 40% of the encapsulated BSA is released
from both microcapsule conditions. The amount of BSA released from the microcapsules
each day proceeding fabrication is given in Figure 3.8 (B). As it is expected, BSA
diffuses out of the microcapsules each day in a sustained release profile. However, more
BSA is released from uncoated alginate microcapsules compared to the chitosan-coated
alginate microcapsules.

Figure 3.8 The accumulated amount of BSA released from both uncoated and chitosancoated alginate microcapsules is quantified by the Bradford colorimetric protein assay
using a spectrophotometer. (A) illustrates the accumulated amount of BSA released from
the microcapsules during the fabrication and washing steps. (B) provides the
accumulated release of BSA curves for uncoated and chitosan-coated microcapsules.
Data are expressed as mean ± standard deviation.
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The encapsulation of FITC-dextran is next investigated. The permeability of
FITC-dextran is evaluated by measuring the fluorescence intensity in the microcapsules
each day using SigmaScan Pro 5.

Figure 3.9 shows the microscopic images of

encapsulated FITC-dextran in uncoated and chitosan-coated alginate microcapsules on
each day for 2 days.

DAY 1

DAY 2

Chitosan-coated
Microcapsules

Uncoated Microcapsules

DAY 0

Figure 3.9 The microphotographs of encapsulated FITC-dextran in uncoated and
chitosan-coated alginate microcapsules are shown above. Images are captured with an
inverted light microscope at 2x magnification.

From the microscopic images in Figure 3.9, it is evident that FITC-dextran is able
to diffuse out of the microcapsules over time. After the first day of incubation in HEPES
buffer solution, a significant amount of FTIC-dextran is released from the uncoated
alginate microcapsules compared to the chitosan-coated alginate microcapsules. By day
2, the fluorescence of the uncoated alginate microcapsules is barely noticeable when
viewed under the inverted light microscope. On the other hand, the fluorescence of the
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chitosan-coated alginate microcapsules is still detectable. The microcapsules are also
observed on day 3, but the data are not presented here. On day 3, the fluorescence of the
uncoated alginate microcapsules is not observed at all. The chitosan-coated alginate
microcapsules are able to display some fluorescence, but it is barely visible. Using the
microscopic images in Figure 3.9, the average fluorescence intensity of the microcapsules
are measured using SigmaScan Pro 5.0.software. The results are presented in Figure
3.10.

Figure 3.10 The average fluorescence intensity of encapsulated FITC-dextran tends to
decrease over time as they are released from the microcapsules. Data are expressed as
mean ± standard deviation.

The plot of average intensity in the microcapsules over time in Figure 3.10
correlates with the visual observation of the fluorescence intensity in the microcapsules in
Figure 3.9. A significant amount of FITC-dextran is released after the first day of
incubation in HEPES buffer solution from the uncoated alginate microcapsules; thus
reducing its average fluorescence intensity from 100% down to 27%. By day 2, the
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average fluorescence intensity is decreased to about 18%.

FITC-dextran is slowly

diffused out of the chitosan-coated alginate microcapsules as their fluorescence remain
strongly evident after the first day. The average fluorescence intensity of the chitosancoated alginate microcapsules decreases from 100% to 90%. By day 2, the average
fluorescence intensity is measured to be about 62%.
The encapsulation of BSA and FITC-dextran studies reveal that the permeability
of chitosan-coated alginate microcapsules is reduced compared to uncoated alginate
microcapsules. This is evident through the slower release of both BSA and FITC-dextran
from the chitosan-coated microcapsules. These studies also prove that the permeability
of the microcapsules can be controlled by coating the alginate microcapsules with
chitosan.

3.5 Microencapsulation of Cells
The effect of the alginate microcapsule microenvironment on cell viability, proliferation,
and differentiation is studied. The encapsulation of fibroblast cells is used to determine if
cells are able to remain viable throughout the fabrication process of the microcapsules
and during incubation. Cell viability is tested by means of live-dead cell and resazurin
assays. The results from the live-dead cell assay are presented in Figure 3.11. The
microcapsules are observed using a fluorescence microscope at 2x magnification.
Microscopic images of phase, live, dead, and live-dead states are taken with a Nikon
digital camera connected to the microscope. The generation of microcapsules by the coaxial air flow method did not significantly affect the viability of encapsulated fibroblast
cells. As it can be seen in Figure 3.11, approximately 70% of the cells remained viable in
both uncoated and chitosan-coated alginate microcapsules following the fabrication
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process.

The results show that fibroblasts cells can be encapsulated in alginate

microcapsules while maintaining their viability.
Chitosan-coated Microcapsules

Live-dead

Dead

Live

Phase

Uncoated Microcapsules

Figure 3.11 Live-dead cell assay for fibroblast cells encapsulated in alginate
microcapsules.
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The resazurin assay is used to determine whether cells are able to remain alive
during incubation for a couple of days. The resazurin assay quantifies the number of
viable cells within the uncoated and chitosan-coated alginate microcapsules over time.
Figure 3.12 illustrates the result from the resazurin assay.

Figure 3.12 The viability of fibroblast cells is examined through a resazurin assay. In
both uncoated and chitosan-coated alginate microcapsules, the number of live cells
decreased over time. Data are expressed as mean ± standard deviation.

Based on the plot in Figure 3.12, the number of viable cells is similar in uncoated
and chitosan-coated alginate microcapsules.

In both cases, the number of viable

fibroblast cells decreases over time during incubation. However, there appears to be
more viable fibroblast cells in the uncoated alginate microcapsules compared to the
chitosan-coated alginate microcapsules. After the first day, about 23% and 16% of the
cells remain viable in uncoated and chitosan-coated alginate microcapsules, respectively.
By day 2, there is an increase in the number of viable cells; but the number continues to
decline for the following days.
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The effect of the microcapsule microenvironment on the proliferation and
differentiation of stem cells is also investigated. Images of encapsulated mouse OCT4GFP embryonic stem cells in uncoated and chitosan coated alginate microcapsules as
well as the GFP expression of the encapsulated cells are provided in Figure 3.13. Images
are taken at 4x magnification with a Nikon digital camera connected to an inverted light
microscope.

Chitosan-coated Microcapsules

GFP Expression

Phase

Uncoated Microcapsules

Figure 3.13 Mouse OCT4-GFP embryonic stem cells are encapsulated in uncoated and
chitosan-coated alginate microcapsules following fabrication. GFP expressions of
encapsulated mouse OCT4-GFP embryonic stem cells are revealed using fluorescence
microscopy. Microscopic images are taken at 4x magnification following microcapsule
fabrication.

Following the encapsulation of mouse OCT4-GFP embryonic stem cells, the
microcapsules are incubated in differentiation medium for 2 days at 37°C and 10% CO2
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with medium change occurring every day.

After 2 days, the proliferation and

differentiation of the stem cells are analyzed using flow cytometry by means of
fluorescence-activated cell sorting (FACS). The proliferation and differentiation of the
encapsulated mouse OCT4-GFP

embryonic stem cells is compared

to the

nonencapsulated state. Figure 3.14 provides the results from flow cytometry analysis.

Figure 3.14 Flow cytometry analysis of encapsulated mouse OCT4-GFP embryonic
stem cells after 2 days of culture. The results reveal that the alginate microcapsule
microenvironment can influence stem cell proliferation and differentiation.

Figure 3.14 shows that about 85% of the mouse embryonic stem cells expressed
the OCT4-GFP gene when encapsulated in uncoated alginate microcapsules. On the
other hand, about 92% of the stem cells expressed the OCT4-GFP gene when
encapsulated in chitosan-coated alginate microcapsules. In summary, less OCT4-GFP
expression means that more of the stem cells had differentiated. More expression of the
OCT4-GFP gene reveals either slower differentiation or undifferentiation of mouse
OCT4-GFP embryonic stem cells.

CHAPTER 4
DISCUSSION

The goal of this study is to optimize the physical properties of alginate-based
microcapsules using a co-axial air flow method and examine how the 3D culture system
of alginate microcapsules affects the proliferation and differentiation of mouse OCT4GFP embryonic stem cells. Prior to the encapsulation of mouse OCT4-GFP embryonic
stem cells, the necessary parameters for the alginate microcapsules are first determined.
In biomedical applications, the microcapsules should have appropriate characteristics
such as a round morphology, large pore sizes, and smooth surfaces in order to properly
facilitate the bi-directional diffusion of the encapsulated material and surrounding
environment.

In addition, the microcapsule properties must be able to support cell

physiological activities, such as metabolism, proliferation, migration, etc. for cell survival
and function [3, 13, 14]. The selected materials for encapsulation fabrication should be
compatible with the encapsulated material such that they do not disrupt its biological
activity [2]. The microcapsules must also be mechanically stable and have long term
integrity. These properties can be achieved by optimizing the size of the microcapsules
to small dimensions. Small microcapsules are found to be mechanically stable due to the
small diameter and large surface area to volume ratio [3, 6, 15]. It is important that
microcapsules maintain the structural integrity and mechanical strength during its
application [3].
In this study, microcapsules are produced by the extrusion of an alginate solution
through a needle gauge with an application of an air flow. Microcapsule size can be
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controlled by process parameters and liquid properties of the extrusion solution. The
optimization of microcapsule size is investigated by varying the needle gauge size, air
flow rate, and alginate concentration.

The experiment of the effect of alginate

concentration on microcapsule size is presented in Appendix. It is found that increasing
the alginate concentration results in larger microcapsules. This is due to the increase in
the viscosity of the alginate solution. Alginate solutions greater than 5% are difficult to
prepare; and therefore is not generally used [9]. It is for this reason that the alginate
concentration must remain below this value. The viscosity of the alginate solution not
only affects microcapsule size, but also the shape of the spheres produced. The spheres
become more spherical as the concentration of the alginate solution is increased. It is
also known that the distance between the tip of the syringe needle and the gelation bath
affects mainly the shape of the drops and thus the microcapsules. Munarin et al. found
that the best results were obtained at a distance of 5cm [1].
Increasing the alginate solution concentration not only results in large
microcapsules, but also in a decrease in microcapsule pore size; thus limiting diffusion
[3]. Microcapsules larger than 1mm suffer from diffusion limitations that can result in
reduced cell growth and cell death for encapsulated cells [16]. As mentioned previously,
a microcapsule of small size with large pores is desired to efficiently facilitate diffusion.
A higher membrane permeability offers a higher rate of nutrient exchange [16].
Therefore, an alginate concentration of low viscosity must be selected in order to produce
small microcapsules with large pores. Based on the effect of alginate concentration on
microcapsule size study, an alginate solution of 1.5% concentration is selected as the
starting microcapsule material.
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Not only must the microcapsules be small and have large pores, but they must
also have a round morphology. Microcapsules are characterized for round morphologies
by measuring their shape factor. The microcapsule can be associated to be a sphere if
their shape factor is 1 or near 1; otherwise it is characterized to be an ellipse. The effect
of needle gauge size and air flow rate on microcapsule size is studied. As it can be seen
from Figure 3.1, microcapsule size decreases as needle gauge size and air flow rate both
increase. Although the increase in air flow can result in smaller microcapsules, the
number of microcapsules with round morphologies tends to decrease even though their
shape factors are estimated to be 0.89. For example, microcapsules are produced by a 30
gauge needle with an alginate concentration of 1.5% and with air flow rates of 0, 7.5, 10,
15, and 20 SCFH.

Air flow rates from 0 – 15 SCFH are able to produce round

microcapsules, but anything higher than 15 SCFH, such as the 20 SCFH air flow rate, the
round morphology of some of the capsules becomes distorted as shown in Figure 4.1. As
a result, 15 SCFH is chosen as the air flow rate for the fabrication of alginate
microcapsules in this study.

Figure 4.1 Alginate microcapsules fabricated from 30 gauge needle, 1.5% alginate
concentration, and 20 SCFH air flow rate result in irregular shaped spheres. Nonspherical shaped microcapsules are indicated by red arrows. Microcapsules are viewed
under an inverted light microscope at 2x magnification.

42
It is important that the microcapsules maintain their structure and stability. Early
rupture of the microcapsules would lead to the release of the entrapped drugs or cells
before its intended application. The stability of the alginate microcapsules is further
examined by adding an additional membrane coating, chitosan, on the surface of the
sphere. Chitosan binds to the surface of the microcapsule thus creating a thin membrane
with small pores.

Chitosan is known to increase the stability of the alginate

microcapsules and is able to minimize the loss of encapsulated material through ionic
cross-linking with the carboxylic residues of sodium alginate.

The electrostatic

interaction between carboxylate groups of alginate and ammonium groups of chitosan
leads to the formation of the chitosan-alginate polyelectrolyte complex [17]. Choosing
the right chitosan concentration to coat the microcapsules is very important. If the
chitosan concentration is too low, the stability of the microcapsules is not sufficient.
However, if the chitosan concentration is too high, the permeability would be reduced
due to the increase in chitosan-alginate complexes; therefore forming a stronger closer
network [17]. A study conducted by Yu et al. demonstrated that 0.4% chitosan solution
had the best reinforcement efficiency resulting in a slower release of the encapsulated
substance [17]. Hence 0.4% chitosan solution is used in this work to coat the alginate
microcapsules.
In this study, we examined the swelling behavior and stability of the alginate
microcapsules. Both uncoated and chitosan-coated alginate microcapsules are incubated
in PBS and monitored for two weeks. The results from the study reveal that uncoated
alginate microcapsules swelled at a faster rate compared to the chitosan-coated alginate
microcapsules. The explanation for the outcome could be that the alginate microcapsule
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surface is directly exposed to the aqueous environment that it is placed in, which is in this
case PBS. Alginate is highly hydrophilic due to the presence of –OH and –COOH groups
in its chains. At neutral pH, water enters the chains of alginate and forms hydrogen
bridges with the –OH and –COO- groups. Consequently, the alginate egg-box model is
slowly weakened and the alginate microcapsules swell. The swelling and rupture of
alginate microcapsules is also due to the precipitation of calcium ions that would reverse
alginate cross-linking when the spheres are incubated in PBS [3]. As there is a gradual
decrease in the number of calcium alginate bonds, there is a decrease in gel strength and
increase in permeability [1, 18, 19]. Adding an additional chitosan membrane on the
alginate microcapsules can minimize the matrix swelling and increase stability. The
chitosan-alginate polyelectrolyte complexes are difficult to break. The importance to
monitor swelling behavior over time is to give an indication of the mechanical properties
and durability of the microcapsules. The aqueous environment is one of the factors
involved in the in vivo release kinetics of cells and drugs [1].
Next, the surface of the alginate microcapsules is characterized using FTIR,
coomassie brilliant blue R-250 staining, and SEM. Each of these studies examine the
absence or presence of chitosan on the surface of the alginate microcapsules. Alginate
and chitosan powders are also scanned by FTIR for comparison with the FTIR spectra of
uncoated and chitosan-coated alginate microcapsules. Recall that the gelation of alginate
occurs when the carboxylate anions of guluronic acid crosslinks with the Ca2+ divalent
cation. In addition, coating of the alginate microcapsules with chitosan occurs when the
ammonium groups of chitosan crosslinks with the carboxylate groups of alginate thus
forming the chitosan-alginate polyelectrolyte complex. FTIR analysis is able to detect
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the structural modifications occurring in the polysaccharides during the formation of
ionic crosslinks and polyelectrolyte complexes.

The formation of crosslinks or

polyelectrolyte complexes modifies the original structure of polysaccharides [1].
Therefore, the FTIR spectra of alginate and chitosan powders shift slightly in the FTIR
spectra of uncoated and chitosan-coated alginate microcapsules though still remaining
similar curves to their individual counterparts. The most important peak that indicates
the presence of chitosan on the alginate microcapsule surface occurs at wavenumber
1564cm-1, which is not present on the uncoated alginate microcapsule spectrum.
The presence of chitosan on the alginate microcapsule surface is also detected
through the staining of the microcapsules with coomassie dye brilliant blue R-250. The
results presented in Figure 3.6 show that the chitosan-coated alginate microcapsules are
stained well when compared to the staining of the uncoated microcapsules.

The

negatively charged coomassie brilliant blue R-250 would strongly bind to the positively
charged chitosan polymer. The uncoated microcapsules are not stained well with the
coomassie dye because the alginate polymer is also negatively charged. The binding of
two negatively charged molecules is undesired. The structure of coomassie brilliant blue
R-250 is illustrated in Figure 4.2.

Figure 4.2 The structure of coomassie brilliant blue R-250 consists of a negatively
charged sulfate group.
Source: Syrovy, L. and Hodny, Z. (1991). Staining and quantification of proteins separated by
polyacrylamide gel electrophoresis. J. Chromatog. 569, 175-196.
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The surface topography of both uncoated and chitosan-coated alginate
microcapsules are observed using SEM. The scanning electron micrographs of uncoated
alginate microcapsules reveal a smooth surface. On the other hand, a few wrinkles,
though not many, can be seen on chitosan-coated microcapsules. This could be due to
the dehydration of the chitosan membrane surrounding the microcapsule [5]. In both
conditions, the microcapsules are able to maintain their round morphology. Remember
that round microcapsules with smooth surface are needed to aid in the diffusion of
molecules into and out of the microcapsules.
Membrane permeability is an important characteristic of microcapsules for the
encapsulation of cells. The permeability of the microcapsules is needed for the diffusion
of oxygen and nutrients into the spheres in order to reach the encapsulated cells for
growth and survival. In addition, diffusion of metabolic waste products and therapeutic
molecules are needed to exit the microcapsules. Low molecular weight substances could
be diffused out quickly and easily from the microcapsules leading to fast release and low
encapsulation efficiency [17]. The permeability of the membrane is dependent on several
properties such as charge distribution, porosity, hydrophilicity, and the properties and
size of the substance being transferred across the membrane. These characteristics vary
depending on the interaction of chitosan with alginate [20].
In this study, the permeability of the microcapsules is tested through the
encapsulation and release of BSA and FITC-dextran.

BSA is chosen for encapsulation

because it is known to be an appropriate model protein in determining the permeability of
microcapsules that are designed for biological systems.

For the fabrication of the

microcapsules, the alginate concentration is increased from 1.5% to 2.5% because it is
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found that the microcapsules produced with 1.5% alginate following the mixing of the
alginate solution with BSA and FITC-dextran resulted in tear drop shaped spheres. This
is due to the dilution of the alginate solution once it is mixed with the encapsulated
material. From the results of the BSA encapsulation study, a possible explanation for the
significant amount of BSA released following fabrication and washing is the shape of the
microcapsules produced. The microcapsules are not observed under an inverted light
microscope for microsphere morphology. Microsphere morphology can greatly influence
drug release behavior. Thus it is important to maintain the round morphology of the
microcapsules. Another reason could be traced to the continuing formation of the ionic
crosslinks and polyelectrolyte complexes of the microcapsules following fabrication.
This would lead to the leakage of some of the encapsulated BSA out of the
microcapsules.
Diffusion of the FITC-dextran molecules through the microcapsules is tracked by
fluorescence microscopy. The results are presented in Figures 3.9 and 3.10. Based on
the release studies of BSA and FITC-dextran, the microcapsules contain pore sizes large
enough for nutrients in the cell culture medium to enter and reach to the encapsulated
cells.

Most differentiation agents, such as growth factors, typically have a lower

molecular weight compared to the 70kDa FITC-dextran.
The microcapsule parameters reflecting cell viability and proliferation have to be
defined for better application. The viability, proliferation, and metabolic activity of cells
within the microcapsule can be influenced by factors such as the fabrication process,
chemical and physical properties of the matrix material, microenvironments, etc. [3]. For
example, recall that alginate solutions of high concentration result in larger size
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microcapsules. The increase of microcapsule diameter would result in the reduction of
cell viability. Alginate solutions with high concentration have higher surface tension,
thus reducing the cell viability in the generated microcapsules [3]. In addition, nutrients
and oxygen would not be able to reach the cells towards the center of the microcapsule as
it would reach the cells on the outer ends in the microcapsule first. This would also result
in a decrease in cell viability. The factors of the fabrication process that can also affect
cell viability include air flow rate, stirring rate of the CaCl2 solution, and extrusion force
(push speed). Effective evaluation of microencapsulated cell viability is highly important
for better bioprocess control and quality assurance [4].
The viability of fibroblast cells encapsulated in alginate microcapsules, both
uncoated and chitosan-coated, after the fabrication process is measured by a live-dead
cell assay. Live-dead cell assay is a simple method involving the staining of cells with
staining solution consisting of an aqueous solution, calcein-AM, and ethidium
homodimer-1. Calcein-AM is a widely used green fluorescent cell marker that readily
passes through the cell membrane and is retained in the cytoplasm of viable cells [11].
The live cells produce a green fluorescence at an excited wavelength of 485 ± 10nm.
Dead cells are labeled with ethidium homodimer-1, emitting red fluorescence at 530 ±
12.5nm [4]. The results of the assay show that some cells are able to remain viable
during the fabrication process of alginate microcapsules.
The viability of the cells in the microcapsules over time is evaluated through the
biochemical assay, resazurin also known as alamar blue. Resazurin is a water-soluble
extracellular redox indicator that can be reduced by living cells. Resazurin assay has its
advantages of being nontoxic to cells and being directly proportional to the number of
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viable cells [4]. The way in which the resazurin assay works is that the oxidized form of
the alamar blue enters the cytosol and is converted to the reduced form by viable cells.
The number of viable cells is related to the amount of the reduced form of alamar blue by
evaluating the absorbance [1].

As presented in Figure 3.12, the number of viable

encapsulated fibroblast cells decreases over time. More viable cells are detected in the
uncoated alginate microcapsules compared to the fibroblast cells encapsulated in
chitosan-coated alginate microcapsules. A possible rationalization for this could be that
the resazurin solution could not easily diffuse into the microcapsules due to the additional
chitosan membrane. Although this additional chitosan membrane provides stability for
the microcapsules, it also reduces the size of the pores thus affecting the diffusion rate
into and out of the spheres. Another reason could be traced back to human error. During
the transfer and washing steps of the microcapsules and the aspiration of the solution in
the wells each day, some of the microcapsules are lost during the process. Cell damage
during the fabrication process may potentially be another explanation for the decrease in
cell viability.
As a result from the two assays, a significant amount of the fibroblast cells
remained viable initially as it is proved by the live-dead cell assay. However, they are
unable to remain alive for a long period of time as it is shown by the results of the
resazurin assay. The explanation can be linked to the fact that the cells are remained in
suspension in the microcapsule despite the diffusion of the necessary nutrients to
maintain cell viability and growth. It is necessary for cells to adhere to a surface in order
to proliferate well.
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Finally, the effect of the 3D microcapsule microenvironment on the proliferation
and differentiation of mouse OCT4-GFP embryonic stem cells is studied. OCT4-GFP is
a transcription factor protein with a green fluorescent protein that expresses a green
fluorescence in undifferentiated embryonic stem cells. It is a frequently used marker for
undifferentiated cells. Image of the nonencapsulated mouse OCT4-GFP embryonic stem
cell subculture expressing the OCT4 gene is presented in Figure 4.3. The subculture is
viewed under a fluorescence microscope at 10x magnification. Image is taken with a
Nikon digital camera connected to the microscope.
Phase

GFP Expression

Figure 4.3 Mouse embryonic stem cells expressing the OCT4-GFP gene by green
fluorescence indicate that the cells are in an undifferentiated state.

After the encapsulation of mouse OCT4-GFP embryonic stem cells, the
microcapsules are incubated in differentiation medium for two days with medium change
occurring every day. On each day of culture, microcapsules are observed by fluorescence
microscopy to detect any GFP expression of the cells within the spheres. After 2 days of
culture, sodium citrate in sodium chloride is used to release the encapsulated mouse
embryonic stem cells from the microcapsules. Sodium and citrate are non-gelling ions
and chealtors that can result in the dissolution of the alginate matrix. The cells are then
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fixed with paraformaldehyde and analyzed using flow cytometry. Flow cytometry is
used because the images by fluorescence microscopy alone are not sufficient enough to
determine the success or failure of mouse embryonic stem cell differentiation. The
results from flow cytometry analysis reveal that mouse embryonic stem cells are able to
differentiate when encapsulated in alginate microcapsules. More differentiated stem cells
are found with the uncoated microcapsules when compared to chitosan-coated
microcapsules. Therefore, the 3D stem cell microenvironment has the ability to control
the proliferation and differentiation of encapsulated mouse OCT4-GFP embryonic stem
cells through microcapsule membrane coating.

CHAPTER 5
CONCLUSION

The main focus of this work is to optimize alginate-based microcapsules using a co-axial
air flow method and study how the microcapsule microenvironment affects the
proliferation and differentiation of mouse OCT4-GFP embryonic stem cells.

The

microcapsule parameters are first determined through a series of experiments that include
the selection of microcapsule fabrication materials and optimization of microcapsule size.
The microcapsules are then tested for mechanical stability and membrane permeability.
Both of these characteristics are important for the application of these microcapsules in
biomedical situations. The viability of cells within the microcapsules is then examined
because it is crucial that cells remain alive prior to their purpose under study. Overall,
the analysis from flow cytometry demonstrates that the microenvironment can control the
proliferation and differentiation of mouse embryonic stem cells.
Some improvements may be necessary in the alginate microcapsule scaffold
presented in this study. Future work can include finding ways to increase the cell
viability within the microcapsules, coating the spheres with additional membranes to
have a better control of the permeability, developing ways to produce uniform-shaped
small spheres, and possibly try to differentiate the mouse embryonic stem cells to a
specific lineage.

Methods for mammalian cell encapsulation are constantly being

improved to achieve smaller size microcapsules, better mechanical stability, lower shear
exerted on the cell suspension during sphere formation, versatility in the selection of
biomaterials, and higher throughput.
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APPENDIX
EFFECT OF ALGINATE CONCENTRATION ON MICROCAPSULE SIZE

Figures A.1 and A.2 show the effect of alginate concentration on microcapsule size.
Alginate concentrations of 1.5%, 2.0%, 2.5%, and 3.0% are tested.

Each alginate

solution is extruded through a 30 gauge needle with an application of 15SCFH air flow
rate at the needle tip into 0.15M CaCl2 solution under gentle stirring.

Figure A.1 Increasing the alginate concentration results in larger size microcapsules.
Alginate microcapsules are swelled and monitored for 4 days.
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